Clinical Trials Directory

Trials / Completed

CompletedNCT01764386

Method-of-Use Study Assessing the Effect of Naltrexone Sustained Release (SR)/ Bupropion SR on Body Weight and Cardiovascular Risk Factors in Overweight and Obese Subjects

A Multicenter, Randomized, Open-Label, Controlled, Method-of-Use Study Assessing the Effect of Naltrexone Sustained Release (SR)/Bupropion SR on Body Weight and Cardiovascular Risk Factors in Overweight and Obese Subjects (The Ignite Study)

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
242 (actual)
Sponsor
Orexigen Therapeutics, Inc · Industry
Sex
All
Age
18 Years – 60 Years
Healthy volunteers
Not accepted

Summary

The purpose of this Phase 3b study is to assess the effects of combination therapy with naltrexone SR/bupropion SR (NB) used in conjunction with a comprehensive lifestyle intervention (CLI) and in a manner consistent with its intended use after marketing approval, on body weight and cardiovascular risk factors compared to the effects of Usual Care in subjects who are overweight with dyslipidemia and/or controlled hypertension or obese. Subjects in the NB and CLI group are required to undergo an evaluation to continue treatment at Week 16. Subjects are to be discontinued from full participation if they do not lose at least 5% of their body weight relative to baseline and/or are experiencing sustained increases in blood pressure (systolic or diastolic) of ≥10 mmHg above baseline. At Week 26, subjects originally assigned to Usual Care switch to treatment with NB and CLI, and subjects assigned to NB and CLI continue treatment for the duration of the study (78-weeks treatment period).

Conditions

Interventions

TypeNameDescription
DRUGNBNaltrexone SR 32 mg/Bupropion SR 360 mg (NB) in combination tablets (daily dosage)
BEHAVIORALCLIThe Comprehensive Lifestyle Intervention (CLI) program includes telephone counseling, internet education, goal setting, and online tracking tools.
BEHAVIORALUsual CareUsual Care is a self-directed lifestyle intervention program

Timeline

Start date
2013-02-01
Primary completion
2014-09-01
Completion
2014-09-01
First posted
2013-01-09
Last updated
2015-12-29
Results posted
2015-11-26

Locations

15 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT01764386. Inclusion in this directory is not an endorsement.